Steve Hall

Esanex, Inc. manufactures and develops drugs for cancer treatment. Its products include orally active Hsp90 inhibitors. The company was founded in 2011 and is headquartered in Indianapolis, IN.

IC Holdings Group, Inc.engages in the provision of an online platform, which delivers solutions for research and development organizations. The company was founded by Alpheus Bingham, Darren J. Carroll, Jeff Hensley, Jill A. Panetta, Yi Shi, and Amiel M. Kornel in 2001 and is headquartered in Waltham, MA.

Numerate, Inc. operates as a technology platform company that leverages proprietary algorithms and cloud computing to transform the drug design process. The company was founded by Guido Lanza, Nigel P. Duffy, John Hampton Griffin and Brandon Allgood in 2007 and is headquartered in San Francisco, CA.

Lysosomal Therapeutics, Inc. engages in the innovation, research, and development in the field of neurodegeneration. It focuses in lysosomal biology in developing novel small molecules for use in the treatment of neurodegenerative diseases. The company was founded by Dimitri Krainc, Joseph Mazzulli, Henri A. Termeer, Robert J. Carpenter, Peter Wirth, Edmund J. Sybertz, and Kees Cornelis Been in 2011 and is headquartered in Cambridge, MA.

Nimbus Apollo, Inc. provides drug discovery research services. The company is headquartered in Cambridge, MA.

Cavion, Inc. engages in development of pharmaceuticals products. It produces oncology drugs to treat solid tumors that selectively inhibits the t-type calcium channel. The company was founded by Andrew J. Krouse, Lloyd S. Gray, and Timothy L. Macdonald in 2005 and is headquartered in Charlottesville, VA.

Forma Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company. engages in the research, development and commercialization of novel therapeutics for the treatment of hematologic diseases and cancers. Its product pipeline consists of FT-4202 for the treatment of sickle cell disease and other hemoglobinopathies, and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company was founded by Michael A. Foley in December 2011 and is headquartered in Watertown, MA.

TEN63 Therapeutics provides drug development services. The American company was founded by Nancy Miller-Rich, Marcel Frenkel, Mark Hallen, Bruce Donald. Marcel Frenkel has been the CEO since incorporation.